CECAD is an inclusive, equal opportunity employer that offers attractive conditions and benefits commensurate with an international research organization with a very collegial and family-friendly work environment.
The Frezza laboratory (https://frezza.cecad-labs.uni-koeln.de/home) seeks to understand the contribution of dysregulated metabolism to ageing-associated disorders, focusing on cancer. A part of the lab is investigating how the loss of the mitochondrial enzyme and tumour suppressor Fumarate Hydratase causes renal cancer. Our work has multiple implications: (1) it will provide a mechanistic understanding of the role of metabolism and small molecule metabolites in human diseases; (2) it will generate experimental and computation tools to identify metabolic vulnerabilities that we can use as pharmacological targets for cancer therapy; (3) it will apply metabolomics and multi-omics analyses, to mouse and human models to identify metabolic markers of disease initiation for clinical application in early detection and for patient stratification.
